baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli) bacteria. Secondly, a new series 4 was designed and assessed against the same bacteria strains, taking the pair of enantiomers 3m/3n as the lead. More than twenty compounds 4 were prepared through a five-step asymmetric synthesis with good enantiomeric excesses (>90%). Interestingly, all compounds of series 3 were efficient on
缺乏具有与耐药菌的传播有关的新颖作用方式的抗生素,使得与传染病的斗争特别具有挑战性。
喹啉核心存在于几种抗感染药中,例如甲
氟喹和苯达
喹啉。这项工作设定了两个主要目标。首先,我们评估了先前的
喹啉3的抗分枝杆菌特性,这些
喹啉已被确认为抗ESKAPEE(粪肠球菌,
金黄色葡萄球菌,肺炎克雷伯菌,鲍曼不动杆菌,
铜绿假单胞菌,肠杆菌属和大肠杆菌)的良好候选者。其次,设计了一个新的系列4并针对相同的细菌菌株进行了评估,以一对3m / 3n对映异构体为首。通过五步不对称合成,以良好的对映体过量(> 90%)制备了二十多种化合物4。有趣的是,系列3的所有化合物对鸟分枝杆菌均有效,MIC = 2–16 µg / mL,而系列4的活性较低。系列3和4通常都比甲
氟喹对ESKAPEE细菌更具活性。根据全球亲脂性,
喹啉4对革兰氏阳性细菌(MIC≤4 µg / mL,4c–4h和4k / 4l)或大肠杆菌(MIC =